Abstract A phase II trial of a single 5-day course of deferoxamine in 9 patients with neuroblastomas was completed. Within 2 days of completion of treatment responses were observed in 7 of 9 patients and there was no drug toxicity. These responses were a decrease in bone marrow infiltration and, in one patient, a measurable reduction in her tumor mass. We conclude that deferoxamine given as an 8-h i.v. infusion daily for 5 days at 150 mg/kg/day has antitumor activity.
EFFECTS OF A SINGLE COURSE OF DEFEROXAMINE IN NEUROBLASTOMA PATIENTS / A., Donfrancesco; G., Deb; Dominici, Carlo; D., Pileggi; Castello, Manuel Adolfo; L., Helson. - In: CANCER RESEARCH. - ISSN 0008-5472. - STAMPA. - 50:16(1990), pp. 4929-4930.
EFFECTS OF A SINGLE COURSE OF DEFEROXAMINE IN NEUROBLASTOMA PATIENTS
DOMINICI, Carlo;CASTELLO, Manuel Adolfo;
1990
Abstract
Abstract A phase II trial of a single 5-day course of deferoxamine in 9 patients with neuroblastomas was completed. Within 2 days of completion of treatment responses were observed in 7 of 9 patients and there was no drug toxicity. These responses were a decrease in bone marrow infiltration and, in one patient, a measurable reduction in her tumor mass. We conclude that deferoxamine given as an 8-h i.v. infusion daily for 5 days at 150 mg/kg/day has antitumor activity.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
